If the story by a small, Philadelphia-based company called Avid Radiopharmaceuticals communicated earlier this month holds up, there will be a reliable diagnostic test for Alzheimer’s disease available in a few years.
Such a test not only would change diagnosis but also help develop novel Alzheimer treatments as it would enable clinical researchers to check whether a drug candidate is making a difference in terms of plaque formation or reduction. At present, the only definite diagnosis of Alzheimer is by brain autopsy.
